Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Monalizumab - Innate Pharma/MedImmune

Drug Profile

Monalizumab - Innate Pharma/MedImmune

Alternative Names: Anti-NKG2A; IPH-22; IPH-2201; IPH-22XX; NN-8765; NNC 0141-0000-0100

Latest Information Update: 01 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer AstraZeneca; Innate Pharma; MedImmune; NCIC Clinical Trials Group; Netherlands Cancer Institute; Novo Nordisk
  • Class Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; NK cell lectin-like receptor subfamily C antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Head and neck cancer; Non-small cell lung cancer
  • Phase I/II Cervical cancer; Chronic lymphocytic leukaemia; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Phase I Haematological malignancies
  • Discontinued Inflammation; Rheumatoid arthritis

Most Recent Events

  • 21 Sep 2020 Medimmune withdraws a planned phase II COLUMBIA-2 trial for microsatellite-stable Colorectal cancer (Combination therapy, adjuvant therapy, First-line therapy) in Australia, Canada, France, South Korea, Spain, Taiwan and in the US (IV), due to change in standard of care landscape (NCT04145193)
  • 22 Jun 2020 Pooled pharmacokinetics data from a phase Ib/II in Solid tumours and phase I/II trial in Head and neck cancer presented at the 111th Annual Meeting of the American Association for Cancer Research (AACR-2020)
  • 04 Jun 2020 Phase-II clinical trials in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in Netherlands (IV) (EudraCT2020-000849-14)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top